ReviewJournal of pharmaceutical analysis2023
Protective effects of catalpol on cardio-cerebrovascular diseases: A comprehensive review.
Review in Journal of pharmaceutical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Canonical Wnt pathway mediates catalpol-induced epithelial differentiation of porcine metanephric mesenchymal cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ginkgolide C alleviates atherosclerosis via activating Nrf2 to inhibit ROS‑dependent NLRP3 inflammasome activation.International journal of molecular medicine · 2026Article
- Iridoids as Multi-target Neuroprotective Agents for Ischemic Stroke: Mechanisms and Therapeutic Potential.Mini reviews in medicinal chemistry · 2026Review
- Catalpol ameliorates diabetic retinal vascular endothelial injury by suppressing NLRP3 inflammasomeInternational journal of ophthalmology · 2026Article
- Research Hotspots and Frontiers of Ischemic Stroke and Traditional Chinese Medicine: A Knowledge Mapping and Text Mining Analysis.Current neuropharmacology · 2026Article
- Irisin, the Myokine: Guardian and Mediator in Cardiovascular System.Endocrinology, diabetes & metabolism · 2025Review
- Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression-A Comprehensive Review.Phytotherapy research : PTR · 2025Review
- A Direct Relationship Between 'Blood Stasis' and Fibrinaloid Microclots in Chronic, Inflammatory, and Vascular Diseases, and Some Traditional Natural Products Approaches to Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- MicroRNAs modulation by curcumin, catalpol, and other natural products in Alzheimer's disease: a review.Molecular biology reports · 2025Review
- Catalpol Protects Against Retinal Ischemia Through Antioxidation, Anti-Ischemia, Downregulation of β-Catenin, VEGF, and Angiopoietin-2: In Vitro and In Vivo Studies.International journal of molecular sciences · 2025Article
- MicroRNA profiling reveals novel biomarkers for cardiovascular and psychological health in plateau psycho CVD.Scientific reports · 2025Article
- Hemodynamic disturbance and mTORC1 activation: Unveiling the biomechanical pathogenesis of thoracic aortic aneurysms in Marfan syndrome.Journal of pharmaceutical analysis · 2025Article
- Trends in extraction and purification methods of Lignans in plant-derived foods.Food chemistry: X · 2025Review
- Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease.Frontiers in pharmacology · 2025Review
- Therapeutic potential of natural products in ischemic stroke: targeting angiogenesis.Frontiers in pharmacology · 2025Review
- Catalpol regulates apoptosis and proliferation of endothelial cell via activating HIF-1α/VEGF signaling pathway.Scientific reports · 2024Article
- Article
- Catalpol promotes hippocampal neurogenesis and synaptogenesis in rats after multiple cerebral infarctions by mitochondrial regulation: involvement of the Shh signaling pathway.Frontiers in pharmacology · 2024Article
- The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway.Drug design, development and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catalpol, an iridoid glucoside isolated from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.